(Q46741012)

24 December 2017

title

Bimodal administration of entacapone in Parkinson's disease patients improves motor control (English)

1 reference

24 December 2017

1 reference

5

1 reference

24 December 2017

Anthony H V Schapira

6

object named as

A H V Schapira

1 reference

24 December 2017

author name string

L Bet

1

1 reference

24 December 2017

S R Bareggi

2

1 reference

24 December 2017

F Pacei

3

1 reference

24 December 2017

G Bondiolotti

4

1 reference

24 December 2017

publication date

1 March 2008

1 reference

24 December 2017

European Journal of Neurology

published in

1 reference

24 December 2017

volume

15

1 reference

24 December 2017

issue

3

1 reference

24 December 2017

page(s)

268-273

1 reference

24 December 2017

Treatment options in the modern management of Parkinson disease

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02043.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02043.X

Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02043.X

On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02043.X

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02043.X

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02043.X

The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02043.X

Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02043.X

Simultaneous determination of levodopa, its main metabolites and carbidopa in plasma by liquid chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02043.X

Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02043.X

The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02043.X

Continuous dopamine-receptor stimulation in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2007.02043.X

10.1111/J.1468-1331.2007.02043.X

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017